Trial · NCT01280604
Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy
NCT01280604, Not applicable, Completed, Kaiser Permanente; results first posted 2015-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy. Trials, record NCT01280604. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01280604
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy
- NCT number
- NCT01280604
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 66 participants, actual
- Lead sponsor
- Kaiser Permanente
- Conditions
- Hyperlipidemias
- Interventions
- Fenofibrate 54mg
- First posted
- 2011-01-21
- Last updated
- 2015-06-08
- Results first posted
- 2015-06-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Triglyceride Levels | 6-10 weeks | Triglyceride levels will be assessed in study participants 6-10 weeks after entry into study. |
| Secondary | Low-density Lipoprotein (LDL) | 6-10 weeks | LDL levels will be assessed in study participants 6-10 weeks after entry into study. |
| Secondary | High-density Lipoprotein,(HDL) | 6-10 weeks | HDL levels will be assessed in study participants 6-10 weeks after entry into study. |
| Secondary | Alanine Aminotransferase(ALT) | 6-10 weeks | ALT levels will be assessed in study participants 6-10 weeks after entry into study. |
| Secondary | Aspartate Aminotransferase (AST) | 6-10 weeks | AST levels will be assessed in study participants 6-10 weeks after entry into study. |
| Secondary | Serum Creatinine(SCr) | 6-10 weeks | SCr levels will be assessed in study participants 6-10 weeks after entry into study. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Triglyceride Levels | 6-10 weeks | milligram/deciliter | MEAN | |
| SECONDARY | Low-density Lipoprotein (LDL) | 6-10 weeks | milligram/deciliter | MEAN | |
| SECONDARY | High-density Lipoprotein,(HDL) | 6-10 weeks | milligram/deciliter | MEAN | |
| SECONDARY | Alanine Aminotransferase(ALT) | 6-10 weeks | international units/liter | MEAN | |
| SECONDARY | Aspartate Aminotransferase (AST) | 6-10 weeks | international units/liter | MEAN | |
| SECONDARY | Serum Creatinine(SCr) | 6-10 weeks | milligram/deciliter | MEAN |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Triglyceride Levels | Intervention | Baseline Triglyceride Levels | 135.5 | Standard Deviation 36.22 | milligram/deciliter |
| Triglyceride Levels | Control | Baseline Triglyceride Levels | 108.3 | Standard Deviation 37.41 | milligram/deciliter |
| Triglyceride Levels | Intervention | Follow-Up Triglyceride Levels | 152.7 | Standard Deviation 42.61 | milligram/deciliter |
| Triglyceride Levels | Control | Follow-Up Triglyceride Levels | 109 | Standard Deviation 39.70 | milligram/deciliter |
| Low-density Lipoprotein (LDL) | Intervention | Baseline Low-density lipoprotein | 95.32 | Standard Deviation 21.32 | milligram/deciliter |
| Low-density Lipoprotein (LDL) | Control | Baseline Low-density lipoprotein | 83.29 | Standard Deviation 22.99 | milligram/deciliter |
| Low-density Lipoprotein (LDL) | Intervention | Follow-up Low-density lipoprotein | 84.42 | Standard Deviation 21.05 | milligram/deciliter |
| Low-density Lipoprotein (LDL) | Control | Follow-up Low-density lipoprotein | 78.71 | Standard Deviation 21.93 | milligram/deciliter |
| High-density Lipoprotein,(HDL) | Intervention | Baseline High-density lipoprotein | 41.88 | Standard Deviation 9.58 | milligram/deciliter |
| High-density Lipoprotein,(HDL) | Control | Baseline High-density lipoprotein | 41.79 | Standard Deviation 14.24 | milligram/deciliter |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention | 33 | |
| Overall Study | STARTED | Control | 33 | |
| Overall Study | Subjects Meeting All Inclusion Criteria | Intervention | 25 | |
| Overall Study | Subjects Meeting All Inclusion Criteria | Control | 29 | |
| Overall Study | COMPLETED | Intervention | 24 | |
| Overall Study | COMPLETED | Control | 28 | |
| Overall Study | NOT COMPLETED | Intervention | 9 | |
| Overall Study | NOT COMPLETED | Control | 5 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention | ||
| Total, all-cause mortality | Control | ||
| Total, other adverse events | Intervention | 0 | 25 |
| Total, other adverse events | Control | 0 | 29 |
| Total, serious adverse events | Intervention | 0 | 25 |
| Total, serious adverse events | Control | 0 | 29 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Intervention vs Control: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01280604
GET https://conductscience.org/api/trials/v1/NCT01280604/results?page=2